Introduction

Entresto, the brand name for sacubitril/valsartan, has become an established therapy in heart failure while entering a new phase commercially. The medicine, developed by Novartis, combines two pharmacological approaches in a single product: neprilysin inhibition through sacubitril and angiotensin II receptor blockade through valsartan. Its clinical importance was established through evidence showing improved cardiovascular outcomes compared with enalapril in patients with heart failure with reduced ejection fraction (HFrEF).

The commercial environment around Entresto is now changing substantially. In the United States, market exclusivity ended in 2025, and generic sacubitril/valsartan products have entered the market. Novartis reported Entresto sales of $7.748 billion in 2025, down 1% in U.S. dollars, with the company attributing the decline to U.S. generic entry during the third quarter. By the second quarter of 2026, quarterly sales had fallen to $1.181 billion, 50% below the prior-year quarter, while ex-U.S. sales continued to grow.

This creates an important case study for the pharmaceutical market. Entresto demonstrates how a medicine can remain clinically relevant while its branded commercial position changes quickly after loss of exclusivity. For healthcare providers and patients, generic competition may expand access and create opportunities for lower-cost treatment. For manufacturers, the product illustrates the value of formulation and patent strategies, regulatory timing, and geographic diversification.

At the same time, clinical research continues to examine sacubitril/valsartan across a broader spectrum of heart failure than the population that established its original evidence base. Recent analyses have provided additional information in patients with mildly reduced or preserved ejection fraction and following worsening heart failure events. The result is a market in which clinical adoption and commercial value are moving in different directions. 

What Is Entresto?

Entresto contains sacubitril and valsartan and belongs to the angiotensin receptor-neprilysin inhibitor (ARNI) class. It received its initial U.S. approval in 2015. 

Sacubitril is a prodrug. Its active metabolite, sacubitrilat, inhibits neprilysin, an enzyme involved in the breakdown of several vasoactive peptides, including natriuretic peptides. Increasing the activity of these peptides can support processes such as vasodilation and natriuresis.

Valsartan works through a different pathway. It blocks the angiotensin II type-1 receptor, reducing the effects of angiotensin II, including vasoconstriction and aldosterone-related sodium and fluid retention. Combining the two mechanisms allows Entresto to influence both counter-regulatory natriuretic peptide pathways and the renin-angiotensin system.

The current U.S. labeling indicates Entresto for reducing the risk of cardiovascular death and hospitalization for heart failure in adults with chronic heart failure, with benefits most clearly evident in patients whose left ventricular ejection fraction is below normal. It is also indicated for symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older.

In Europe, the authorized indication is more specifically defined around symptomatic chronic heart failure with reduced ejection fraction in adults, while pediatric use applies to children and adolescents from one year of age with symptomatic chronic heart failure and left ventricular systolic dysfunction. The European product information was updated in January 2026.

The medicine is available as tablets and, in the United States, as oral pellets for pediatric use. Its labeling also contains important safety considerations involving fetal toxicity, angioedema, hypotension, renal function, and potassium levels. These considerations influence clinical monitoring and the practical use of the therapy. 

Recent Developments and Trends in Entresto

Clinical evidence continues beyond the original HFrEF population. 

Entresto's commercial history is closely linked to PARADIGM-HF, one of the landmark trials in modern heart failure treatment. The study enrolled 8,442 adults with symptomatic chronic heart failure and left ventricular systolic dysfunction. Sacubitril/valsartan reduced the risk of cardiovascular death or hospitalization for heart failure compared with enalapril, with a hazard ratio of 0.80.

These results helped establish ARNI therapy as an important component of guideline-directed treatment for HFrEF. The 2022 AHA/ACC/HFSA heart failure guideline recommends an ARNI, ACE inhibitor, or ARB as first-line renin-angiotensin system inhibition for HFrEF and recommends switching appropriate symptomatic patients from an ACE inhibitor or ARB to an ARNI.

The clinical question subsequently expanded: could sacubitril/valsartan provide similar value when ejection fraction is above the conventional HFrEF range?

PARAGON-HF did not meet its primary endpoint with statistical significance in patients with ejection fraction of at least 45%. The rate ratio for the composite of total heart failure hospitalizations and cardiovascular death was 0.87, with a 95% confidence interval of 0.75 to 1.01. Nevertheless, the results suggested potential differences according to ejection fraction and patient characteristics.

Subsequent pooled analyses have strengthened interest in this broader population. A participant-level analysis of PARAGLIDE-HF and PARAGON-HF found that sacubitril/valsartan reduced total worsening heart failure events and cardiovascular death compared with valsartan, with a larger apparent treatment effect among patients with ejection fraction at or below 60%.

Another pooled analysis combining PIONEER-HF and PARAGLIDE-HF included 1,347 patients hospitalized or recently hospitalized for worsening heart failure. Sacubitril/valsartan produced a 24% greater reduction in NT-proBNP compared with control treatment and was associated with a 30% lower risk of cardiovascular death or heart failure hospitalization. The treatment effect was consistent across ejection fractions up to 60%, although symptomatic hypotension was more frequent.

These findings do not mean that every potential use of sacubitril/valsartan has become an approved indication. Instead, they demonstrate how post-approval evidence can influence treatment guidelines, physician perception, and future commercial opportunities. 

Pediatric heart failure remains an important segment

Entresto is also notable for its pediatric indication. The FDA added the pediatric heart failure indication in 2019 for patients one year of age and older with symptomatic heart failure and systemic left ventricular systolic dysfunction.

The pediatric market is much smaller than the adult heart failure population, but it has strategic importance because few therapies have extensive evidence and regulatory labeling across pediatric age groups. Entresto's availability in pediatric formulations, including oral pellets, addresses a practical administration requirement that differs from the adult market.

The FDA continued postmarketing review of Entresto in pediatric patients in 2025, illustrating the ongoing regulatory attention associated with long-term use in younger populations.

Generic competition has changed the U.S. commercial model

The most important recent commercial development is generic entry.

The FDA approved the first generic versions of Entresto in May 2024. These approvals included sacubitril/valsartan tablets in the three principal strengths and were therapeutically equivalent to the reference product, subject to applicable patent and exclusivity considerations.

Novartis subsequently reported that U.S. market exclusivity was lost in July 2025. The company's 2025 annual report stated that Entresto sales declined after generic entry in the United States during the third quarter.

The impact became more pronounced in 2026. In the second quarter, Novartis reported $1.181 billion in Entresto sales, compared with $2.357 billion in the same quarter of 2025. That represented a 50% decline in U.S. dollar terms and a 51% decline at constant exchange rates. First-half 2026 sales were $2.486 billion, down 46% in U.S. dollars.

This is not simply a decline in product demand. It reflects the normal commercial consequences of generic competition: lower branded volume, price pressure, substitution, payer influence, and redistribution of market share among manufacturers.

International markets provide a different commercial picture

The global Entresto market is not moving uniformly. Novartis reported that Entresto continued to grow outside the United States in 2026.

This geographic difference matters because patent and regulatory-exclusivity timelines are not identical across countries. Novartis reported that European regulatory data protection for Entresto expires in November 2026, while the company continues to pursue intellectual-property protection associated with later-expiring rights.

The result is a staggered market transition rather than a single global loss of exclusivity event. 

Impact on the Healthcare Industry

Entresto has influenced heart failure management by shifting the treatment discussion from conventional renin-angiotensin system blockade toward combined neprilysin and angiotensin receptor inhibition.

For hospitals and cardiology practices, the medicine is particularly relevant because heart failure hospitalization is a major driver of healthcare utilization. The PARADIGM-HF findings and subsequent evidence supporting earlier initiation have encouraged healthcare systems to consider how guideline-directed therapies are introduced during and after hospitalization.

The 2022 AHA/ACC/HFSA guideline specifically supports initiation of ARNI therapy in appropriate hospitalized patients before discharge. This creates an operational dimension to Entresto adoption. Successful implementation requires medication reconciliation, blood-pressure assessment, renal and potassium monitoring, payer authorization where applicable, and coordination between inpatient and outpatient teams.

Generic competition could change this equation. Lower-cost sacubitril/valsartan products may make ARNI therapy easier to incorporate into formularies and discharge protocols where cost has previously limited uptake. At the same time, healthcare systems will need to manage multiple manufacturers and ensure reliable supply and appropriate product substitution.

For pharmaceutical companies, the Entresto experience demonstrates that clinical differentiation can create a large market but cannot indefinitely protect branded revenue. Once therapeutic equivalence is established for generics, competition increasingly shifts toward manufacturing efficiency, supply reliability, contracting, distribution, and price. 

The impact also extends to research. Evidence generated after initial approval can expand understanding of where an established therapy may have the greatest clinical value. For Entresto, research in HFmrEF, HFpEF, and worsening heart failure has created a more nuanced view of the potential patient population than the original HFrEF evidence alone. 

Market and Business Implications

Genericization is the defining market force

Entresto provides a clear example of the economic transition that occurs when a blockbuster cardiovascular medicine loses exclusivity.

Novartis generated $7.748 billion in Entresto sales during 2025, making it one of the company's largest products. Yet the impact of U.S. generic entry became highly visible within months. By 2026, the U.S. commercial environment was fundamentally different.

For generic manufacturers, the opportunity is substantial because the reference product established a large and clinically accepted treatment category. The FDA's approval of generic products from manufacturers including Alembic Pharmaceuticals, Laurus Labs, and Crystal Pharmaceutical provides evidence of a competitive manufacturing base. 

The opportunity is not limited to obtaining regulatory approval. Manufacturers must establish reliable active pharmaceutical ingredient supply, production capacity, quality systems, distribution relationships, and payer access. In a mature generic market, price competition can be intense, making manufacturing efficiency particularly important. 

Clinical familiarity supports adoption potential

Unlike a newly launched generic entering an uncertain therapeutic category, sacubitril/valsartan benefits from years of physician familiarity and extensive clinical evidence.

The commercial question therefore shifts from whether physicians understand the therapy to how quickly generic substitution occurs and how formularies, insurers, hospitals, and pharmacies manage the transition.

Clinical familiarity may support continued demand for the active ingredients even as the branded product loses share. This creates a distinction between market demand for sacubitril/valsartan and demand for branded Entresto. The former may remain resilient even while the latter contracts.

Pricing and reimbursement are becoming more important

Heart failure is a chronic condition requiring long-term treatment, making drug affordability an important factor in adherence and healthcare-system economics. 

Generic competition generally creates the potential for lower acquisition costs, although actual patient savings depend on insurance design, formulary placement, dispensing arrangements, local pricing, and manufacturer competition. 

For payers, sacubitril/valsartan creates an interesting balance. The therapy has a higher-value clinical profile than many older renin-angiotensin system medicines, but generic availability changes the economic calculation. Health plans can potentially capture greater value when clinically effective therapy becomes available at lower generic prices. 

Intellectual property remains strategically relevant

The Entresto case also illustrates why pharmaceutical companies develop multiple layers of intellectual property around complex products.

Novartis has reported patents associated with the combination, crystalline forms, and dosing regimen. Some U.S. patents have expired, while others expire later. The company has also disclosed litigation involving generic manufacturers.

This does not guarantee continued branded exclusivity. Instead, it demonstrates how patent portfolios can affect the timing and structure of generic competition. 

For market analysts, evaluating loss-of-exclusivity risk therefore requires more than identifying a single patent expiry date. Regulatory exclusivity, formulation patents, litigation outcomes, settlement arrangements, manufacturing capabilities, and generic launch strategies can all influence the actual timing and intensity of competition. 

Key Companies and Industry Participants

Novartis

Novartis developed and originated Entresto and remains responsible for the branded product. The company's current strategy reflects a shift from defending a high-value mature brand toward managing the commercial consequences of genericization while maintaining the medicine's international business.

Entresto remains one of Novartis' largest products, but its contribution to the company's portfolio is declining as generic competition expands. Novartis is increasingly balancing mature-product erosion with investment in newer growth brands and pipeline assets.

Generic manufacturers

Alembic Pharmaceuticals, Laurus Labs, and Crystal Pharmaceutical were among the companies receiving FDA generic approvals in 2024. Their entry illustrates the broader transition from a single-brand market toward a multi-manufacturer environment.

Other manufacturers may also compete as regulatory and commercial conditions evolve. The competitive advantage in this stage of the product lifecycle is likely to depend on cost structure, manufacturing scale, supply reliability, contracting, and distribution rather than traditional brand promotion.

FDA and EMA

Regulatory agencies remain central to the market because they define approval, therapeutic equivalence, labeling, safety monitoring, and pediatric requirements. 

The FDA's approval of generic sacubitril/valsartan created the regulatory foundation for U.S. competition. The EMA's continued maintenance and updating of Entresto's product information provides the regulatory framework for European use.

Cardiology and heart failure organizations

The AHA, ACC, HFSA, and European cardiology organizations influence adoption through clinical guidelines and interpretation of evidence. Their recommendations can materially affect prescribing patterns and therefore market demand.

The growing evidence base around sacubitril/valsartan in different ejection-fraction categories also illustrates how clinical organizations can influence the commercial relevance of an established medicine long after its original approval.

Challenges and Limitations

Despite its established clinical position, Entresto faces several challenges

First, generic competition can reduce branded revenue rapidly. The 2026 Novartis sales data demonstrate the scale of this effect. For the originator, maintaining commercial value becomes increasingly difficult once lower-cost therapeutically equivalent products are available.

Second, affordability does not automatically translate into universal access. Insurance design, formulary decisions, prescribing practices, healthcare infrastructure, and patient adherence continue to affect real-world use.

Third, sacubitril/valsartan requires clinical monitoring. Hypotension, hyperkalemia, renal impairment, and angioedema remain relevant safety considerations. These factors can influence treatment selection and persistence in some patient populations.

Fourth, evidence outside classic HFrEF requires careful interpretation. PARAGON-HF did not achieve a statistically significant primary endpoint, while later pooled analyses suggest greater benefit in particular subgroups. This supports a targeted evidence-based approach rather than assuming uniform efficacy across all heart failure phenotypes.

Finally, international market fragmentation presents a commercial challenge. Patent and regulatory-exclusivity timelines differ across regions, meaning manufacturers must develop country-specific launch and supply strategies.

Future Outlook for Entresto

The future of Entresto is likely to be defined by two parallel developments: continued clinical relevance and declining branded exclusivity.

In the United States, generic competition is expected to remain the dominant commercial force. The sharp fall in Novartis' 2026 sales demonstrates that the branded market has already entered a post-exclusivity phase. Competitive pricing, pharmacy substitution, payer contracting, and manufacturing scale are likely to become more important than brand differentiation.

Outside the United States, the trajectory is different. Novartis continues to report ex-U.S. growth, but European regulatory protection is approaching another important transition point. This makes geographic diversification valuable in the short term while also indicating that additional markets may eventually face generic pressure.

Clinically, research into sacubitril/valsartan across the heart failure spectrum remains relevant. Evidence from pooled analyses suggests particular interest in patients with mildly reduced or preserved ejection fraction, especially those with lower ejection fractions within those categories or recent worsening heart failure. Whether future evidence or guidelines expand the role of ARNI therapy further will depend on clinical outcomes, comparative evidence, and regulatory decisions.

The pediatric segment will remain another specialized area. Entresto's pediatric labeling and formulation capabilities give the product a position that generic manufacturers must also address if they seek broad market participation.

For pharmaceutical companies, the larger lesson is the importance of planning for the entire product lifecycle. Entresto demonstrates how a medicine can move from innovation-driven premium pricing to evidence-driven mature-market competition. The commercial value of the active ingredient can persist even when the originator brand experiences a substantial revenue decline.

Conclusion

Entresto has moved from being a major branded innovation in heart failure to becoming one of the most closely watched examples of generic transition in cardiovascular pharmaceuticals. Its combination of sacubitril and valsartan established the ARNI class as an important treatment strategy, supported by strong evidence in HFrEF and reinforced by guideline recommendations.

The market story is now changing. U.S. generic entry in 2025 has produced a sharp reduction in Novartis' branded sales, with the decline accelerating through the first half of 2026. At the same time, sacubitril/valsartan remains clinically established, and evidence from newer analyses continues to inform its potential role across broader heart failure populations.

For healthcare systems, generic competition could improve the economic accessibility of an established therapy. For generic manufacturers, Entresto represents a sizeable and clinically mature market where execution, supply reliability, pricing, and regulatory compliance are central to competitiveness. For Novartis, the product illustrates the financial impact of loss of exclusivity and the importance of managing mature brands alongside newer growth assets.

Entresto therefore remains important for two different reasons. Clinically, it continues to shape heart failure treatment. Commercially, it offers a clear view of how innovation, intellectual property, generic competition, reimbursement, and real-world adoption interact over the lifecycle of a major pharmaceutical product.

Sources

• U.S. Food and Drug Administration - Entresto Prescribing Information and Generic Drug Approvals
• European Medicines Agency - Entresto European Public Assessment Report and Product Information
• Novartis - Annual Report 2025
• Novartis - Q1 and Q2 2026 Financial Reports
• American Heart Association / American College of Cardiology / Heart Failure Society of America - 2022 Guideline for the Management of Heart Failure
• New England Journal of Medicine - PARADIGM-HF and PARAGON-HF
• European Heart Journal / PubMed - PARAGLIDE-HF and PARAGON-HF pooled analyses
• PubMed - PIONEER-HF and PARAGLIDE-HF pooled analysis
• Indian Heart Journal / PubMed - PARADIGM-HF India Sub-study
• DailyMed - Current U.S. Entresto Label